Welcome to our dedicated page for Inspire Medical Systems SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Inspire Medical Systems's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Inspire Medical Systems's regulatory disclosures and financial reporting.
An INSP shareholder filed a Rule 144 notice to sell 109 shares of common stock. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC at an aggregate market value of $10,355.00, with the shares listed on the NYSE. The shares were acquired on 06/28/2024 through an employee stock purchase plan from the issuer for cash, and the planned sale date is approximately 01/09/2026. By signing the notice, the seller represents they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Inspire Medical Systems, Inc. director insider sale reported
Director Shawn T. McCormick reported selling 1,200 shares of Inspire Medical Systems, Inc. common stock on 12/02/2025 at a price of $139 per share. After this transaction, he beneficially owns 24,846 shares directly and 3,000 shares indirectly through a trust. The filing notes that all sale transactions were made under a Rule 10b5-1 trading plan dated August 29, 2025, which is a pre-arranged plan for trading company stock.
Inspire Medical Systems had an affiliate file a Form 144 notice to potentially sell 1,200 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 12/02/2025. The shares have an aggregate market value of $151,608.00 based on the information provided. Common shares outstanding were 29,056,434 at the time referenced. The seller acquired these 1,200 shares on 03/17/2023 by exercising stock options and paying in cash on that date.
Over the past three months, the same account conducted 10b5-1 sales of 2,000 common shares on 11/28/2025, generating gross proceeds of $254,960.00. The notice includes a representation that the seller does not know of undisclosed material adverse information about the issuer’s current or prospective operations.
Inspire Medical Systems director reports planned stock sale
A director of Inspire Medical Systems reported selling 2,000 shares of common stock on 11/28/2025 at a price of $127.48 per share. After this sale, the director beneficially owns 26,046 shares directly and 3,000 shares indirectly through a trust. The filing notes that all sale transactions were made under a Rule 10b5-1 trading plan dated August 29, 2025, which is a pre-arranged program for trading company stock.
An affiliate of the issuer filed a Form 144 notice to sell 2,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate aggregate market value of $254,660. The filing lists total shares of this class outstanding as 29,056,434.
The shares to be sold were acquired on 03/17/2023 by exercising stock options granted by the issuer, with the purchase price paid in cash on the same date. This notice reflects a planned sale by or for the account of a person related to the issuer under Rule 144, and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Inspire Medical Systems, Inc. (INSP) director Myriam J. Curet, M.D. reported several small transactions in the company’s common stock on a Form 4. The filing shows open‑market purchases and sales between $77.2754 and $163.8388 per share, leaving her with 3,365 shares of common stock held directly after the last reported transaction on 08/08/2025.
The filing explains that some trades occurred inadvertently through a pooled investment vehicle that did not filter out Inspire’s securities. It also notes that a May 8, 2025 sale of 1 share at $153.2237 was matchable under Section 16(b) with a prior April 7, 2025 purchase of 1 share at $148.262. Dr. Curet paid the company $4.97, representing the full short‑swing profit from that transaction.
Inspire Medical Systems, Inc. expects to release a significant portion of the valuation allowance on its U.S. deferred tax assets in the fourth quarter of fiscal 2025. The company estimates this action will create an income tax benefit of $90 million to $100 million for the year. This tax benefit is expected to increase diluted earnings per share by approximately $3.00 to $3.30 for the same period. These figures are based on current assumptions and are described as forward-looking, with actual results potentially differing due to various risks and uncertainties discussed in the company’s other regulatory filings.
Inspire Medical Systems (INSP): Schedule 13G/A update — Dragoneer Investment Group, LLC and Marc Stad filed Amendment No. 1 reporting beneficial ownership of the company’s common stock at 0 shares, representing 0% of the class.
The filing notes ownership of 5 percent or less and lists no voting or dispositive power. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The date of event is 09/30/2025.
Inspire Medical Systems, Inc. (INSP) disclosed that investment entities affiliated with Deerfield, including Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and individual investor James E. Flynn, have each reported beneficial ownership of the same block of 1,476,303 shares of Inspire Medical common stock. This position represents 5.08% of the company’s outstanding common stock.
The Deerfield entities and Flynn report shared voting and dispositive power over all 1,476,303 shares and no sole voting or dispositive power. They also certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Inspire Medical, indicating a passive investment stance under the Schedule 13G framework.
Wasatch Advisors LP filed Amendment No. 1 to Schedule 13G for Inspire Medical Systems (INSP), reporting beneficial ownership of 135,914 common shares, representing 0.5% of the class as of September 30, 2025.
The firm holds sole voting and sole dispositive power over all reported shares. It certified the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.